Author Archives: Alice Melao

Recordati Acquires Global Rights Over Signifor and Osilodrostat

Recordati has acquired worldwide rights over Novartis‘ investigational therapy osilodrostat (LCI699), being developed for the treatment of endogenous Cushing’s disease. The agreement also covers Signifor (pasireotide), an approved treatment for adults with Cushing’s disease who failed surgery or who were not eligible for surgery,…

Targeted Radiosurgery Suitable for Youngsters with Cushing’s Disease and Acromegaly, Study Shows

Stereotactic radiosurgery — a targeted form of radiation therapy — can effectively reduce hormone levels and control tumor progression in children and adolescents with hormone-secreting pituitary adenomas, particularly those with Cushing’s disease and acromegaly, a retrospective study shows. The study, “Outcomes after Gamma knife Stereotactic Radiosurgery in pediatric…